YOSH OLIMLAR
ILMIY-AMALIY KONFERENSIYASI
in-academy.uz/index.php/yo
40
THE POTENTIAL OF BACTERIOPHAGE THERAPY AS AN ALTERNATIVE
TREATMENT FOR ANTIBIOTIC-RESISTANT INFECTIONS
Saidova Mahliyo Bakhtiyor kizi
Assistant at the Alfraganus University
Email: mahliyosaidova1416@gmail.com
https://doi.org/10.5281/zenodo.14020902
Introduction
Bacteriophages, or phages, are viruses found abundantly in the environment and have
the ability to infect, replicate within, and ultimately destroy bacteria in a highly specific
manner during their lytic phase. Unlike antibiotics, phages have a much narrower host range,
making them a promising supplement or even alternative to antibiotic therapy, particularly
when combating multiple drug-resistant (MDR) bacterial infections, where antibiotics often
fail. The concept of bacteriophage therapy is not new. In fact, bacteriophages were first
identified in the early 20th century, with Felix d'Herelle pioneering their therapeutic use after
British bacteriologist Frederick W. Twort first described bacterial lysis in 1915. The former
Soviet Union consistently used phages to treat infections like gastrointestinal diseases and gas
gangrene in soldiers. However, in the Western world, phage therapy fell out of favor following
the discovery of penicillin after World War II.
The overuse of antibiotics in medicine, agriculture, and animal farming during the
"golden era" of antibiotics has led to a significant rise in MDR bacteria, now a critical global
health issue. Currently, MDR bacterial infections are responsible for approximately 1.27
million deaths annually worldwide, and it is estimated that this number could rise to 10
million by 2050. Given the diminishing effectiveness of traditional antibiotics, the re-
emergence of bacteriophages, bacteria’s natural predators, offers a potential solution to this
growing public health crisis.
Despite their previous widespread use, there has been relatively little scientific research
on bacteriophage therapy in recent decades. As a result, most of the current evidence
regarding its safety and efficacy comes from case reports, preclinical studies, and a limited
number of early randomized controlled trials (RCTs), which still present certain limitations.
This bibliometric analysis aims to provide an in-depth overview of the existing literature
on the therapeutic use of bacteriophages. It also seeks to highlight ongoing efforts to establish
a robust evidence base through RCTs, while assessing both the potential benefits and
challenges of reviving this historical yet promising treatment approach.
Keywords
: Bacteriophages, Phage therapy, Randomized-controlled trials.
Methods
Bibliometric Analysis
Data for this bibliometric analysis were obtained from the Web of Science (WoS)
database, specifically from the SCI-Expanded sub-database. WoS covers a broad range of
approximately 34,000 journals, with over 75 million records, including resources like the
Science Citation Index, Social Sciences Citation Index, Arts and Humanities Citation Index,
Conference Proceedings Citation Index, Book Citation Index, and Emerging Sources Citation
Index. The Thomas Scientific impact factor is also derived from data within the WoS database.
The search was conducted using the keywords: “bacteriophage” OR “phage” AND
“therapy” OR “application.” Articles published between January 1, 1965, and December 31,
YOSH OLIMLAR
ILMIY-AMALIY KONFERENSIYASI
in-academy.uz/index.php/yo
41
2023, were included, with no language restrictions. To ensure relevance and accuracy, two
authors independently reviewed the titles and abstracts to confirm alignment with the
research topic.
Data were extracted in January 2024, and the information was exported in plain text
format and organized into tables. The extracted data included publication year, total citations,
citations per year, author affiliations, journal publications, subject areas, article types, and
countries of origin.
Results
Bibliometric Analysis
A total of 6,355 articles were included in the analysis, which collectively received
215,209 citations (157,789 excluding self-citations), resulting in an average of 33.9 citations
per article and an H-index of 178. Over the last decade, the number of publications on
bacteriophage therapy has more than tripled, increasing from 212 articles in 2011 to 739
articles in 2023. The majority of these articles were written in English (98.9%), with smaller
contributions in French (0.3%) and German (0.2%). Most of the publications were original
research articles (4,886, 76.8%), followed by reviews (1,187, 18.7%) and editorials (131,
2.1%). The remaining publications consisted of meeting abstracts, proceedings, book
chapters, and letters to the editor. These articles were distributed across 923 different
journals (Table 1). A total of 24,005 distinct authors contributed to the literature, with the
highest proportion of articles coming from the USA (28.2%), followed by China (16.0%), the
UK (7.8%), Germany (7.5%), and Poland (5.1%).
Systematic Review
A systematic search of PubMed, using the filter "randomized controlled trial," identified
44 articles for potential retrieval. Of these, only 7 articles met the eligibility criteria for
inclusion, involving a total of 418 participants. Mild to moderate adverse events related to
phage therapy were reported in 10 out of 195 participants (5.1%) across three studies. One
study tested phages in healthy participants. The treatment indications in these studies
included bacterial diarrhea, urinary tract infections, infected burn wounds, chronic otitis,
chronic venous leg ulcers, and chronic rhinosinusitis. Three of the studies demonstrated a
statistically significant difference in outcomes when comparing single-phage therapy to the
standard of care or placebo.
Discussion
The goal of this bibliometric analysis was to provide an overview of the current state of
the literature regarding the therapeutic use of bacteriophages. Our findings show a clear
upward trend in citations on this topic, suggesting that phage therapy is gaining significant
attention within the research community.
The most frequently cited paper in our analysis was published in 2001. It reviewed
studies conducted in Poland and the former Soviet Union, comparing phages with antibiotics
and addressing early challenges in phage therapy research. This work paved the way for
future advancements in the therapeutic application of phages. The second and third most
cited publications also explored the potential of phages. Notably, the 2007 study by Lu and
Collins demonstrated the effectiveness of engineered phages in biofilm removal, highlighting
the practicality of synthetic biology for manipulating these viruses. Additionally, Schooley and
colleagues detailed methods for designing therapeutic phage cocktails and developing
YOSH OLIMLAR
ILMIY-AMALIY KONFERENSIYASI
in-academy.uz/index.php/yo
42
personalized treatments for diabetic patients with necrotizing pancreatitis complicated by
MDR Acinetobacter baumannii infections.
One of the main barriers to the widespread implementation of phage therapy has been
the limited availability of clinical data regarding its safety and efficacy. Out of an initial pool of
6,355 articles, only 7 randomized controlled trials (RCTs) were identified, involving a total of
418 participants. Consequently, much of the current evidence is derived from case studies,
with over 2,200 applications of phage therapy in hard-to-treat infections reported. This
discrepancy may be attributed to regulatory constraints, as phage therapy remains classified
as an unapproved medical product under Article 37 of the World Medical Association's
Declaration of Helsinki. The personalized nature of phage therapy, along with challenges in
accessing effective phages, has further limited the availability of clinical data.
Additionally, issues such as intellectual property concerns and a lack of interest from
pharmaceutical companies have slowed the advancement of phage therapy. To overcome
these obstacles, it may be necessary for government sectors to step in, creating a more
favorable investment climate for pharmaceutical companies or offering greater support to
research initiatives. Such measures could promote collaboration and stimulate further
exploration, potentially accelerating the development of phage therapy and its incorporation
into mainstream medical practice.
Limitations
Bibliometric analysis is a useful tool for assessing research impact, influence, and trends,
but it comes with several limitations that must be considered. First, the analysis is based
solely on published studies, which may lead to an incomplete view of the total research
activity in the field of phage therapy. Unpublished or gray literature, such as conference
proceedings, might not be included. Additionally, the search in the Web of Science (WoS)
database focuses on citations, abstracts, and keywords, which could result in the omission of
relevant articles that only mention the key terms in their methods sections. This limitation
may affect the comprehensiveness of the list of identified articles on phage therapy.
Furthermore, the analysis is based on citation counts alone, which may not necessarily
reflect the quality of the research. Factors like the age of the study, the journal in which it was
published, and whether it is open-access can all influence citation counts. Therefore, the
results might not fully represent the true quality of the research. It is important to recognize
that a study with fewer citations might be of higher quality than one with a larger citation
count.
Conclusions
In summary, phage therapy has gained increasing attention as a potential complement
to antibiotics in recent years. While randomized controlled trials (RCTs) across various
indications have demonstrated the safety of phage therapy, the lack of robust in vivo evidence
remains a key obstacle to its broader acceptance. These limitations are often linked to issues
with study design. Additionally, a deeper understanding of phage pharmacology is essential,
as it often poses challenges to the effective clinical application of phages. For phage therapy to
be successfully integrated into clinical practice, researchers and clinicians must learn from
past experiences and rigorously address critical aspects in future trials, such as phage
preparation quality, sensitivity testing, titers and dosages, access to infection sites, and
YOSH OLIMLAR
ILMIY-AMALIY KONFERENSIYASI
in-academy.uz/index.php/yo
43
stability. Furthermore, the establishment of standardized treatment protocols will be
essential to optimize the efficacy of phage therapy.
References:
1.
Clokie MR, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage.
2011;1:31–45. [
2.
Romero-Calle D, Guimarães Benevides R, Góes-Neto A, Billington C. Bacteriophages as
alternatives to antibiotics in clinical care. Antibiotics. 2019;8(3):138. [
3.
Twort FW. An investigation on the nature of ultra-microscopic viruses. Lancet.
1915;186(4814):1241–3. [
4.
Krestovnikova VA. Phage treatment and phage prophylactics and their approval in the
works of the Soviet researchers: Springer; 1947. p. 56–65. [
5.
Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics.
Clin Infect Dis. 2013;56(10):1445–50. [
6.
Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T.
2015;40(4):277–83. [
7.
Antimicrobial Resistance Collaborators . Global burden of bacterial antimicrobial
resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. [
8.
de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 million people die a year due to
antimicrobial resistance by 2050? PLoS Med. 2016;13(11):e1002184. [
9.
Moelling K, Broecker F, Willy C. A wake-up call: we need phage therapy now. Viruses.
2018;10(12):688. [
10.
Górski A, Borysowski J, Międzybrodzki R. Phage therapy: towards a successful clinical
trial. Antibiotics. 2020;9(11):827. [
11.
Birkle C, Pendlebury DA, Schnell J, Adams J. Web of Science as a data source for research
on scientific and scholarly activity. Quan Sci Stud. 2020;1:363–76. [
